Repare Therapeutics’ (RPTX) “Market Perform” Rating Reiterated at Lifesci Capital

Lifesci Capital reaffirmed their market perform rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a report issued on Friday morning,Benzinga reports.

Several other research analysts have also commented on RPTX. Stifel Nicolaus reduced their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Friday, November 8th.

Repare Therapeutics Stock Down 55.4 %

Shares of NASDAQ:RPTX opened at $1.77 on Friday. The firm has a 50 day moving average of $3.30 and a 200 day moving average of $3.35. The company has a market capitalization of $75.24 million, a price-to-earnings ratio of -0.89 and a beta of 0.71. Repare Therapeutics has a 52 week low of $1.66 and a 52 week high of $8.49.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after purchasing an additional 7,800 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after acquiring an additional 4,000 shares during the period. XTX Topco Ltd acquired a new position in shares of Repare Therapeutics in the 2nd quarter valued at $110,000. Exchange Traded Concepts LLC raised its stake in Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after acquiring an additional 8,809 shares during the last quarter. Finally, Stifel Financial Corp grew its stake in Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after purchasing an additional 13,800 shares during the last quarter. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.